Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 141

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 141
---
/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |
| Singapore     |     | Microneedle arrays for cancer therapy applications |     |     1002004900T |     | 11/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |

<div align='center'>97</div>

| Country 
 Name    |     | Title                                              |     | Application     
 No.             |     | Priority  
 Date      |     | Filed Date |     | Patent No. |     | Issue Date |     | Projected  
 Expiration 
 Date       |     | Status  |     | Assignee(s)                                                                                         |
| Korea   |     | Microneedle arrays for cancer therapy applications |     | 10-2024-7043044 |     | 11/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |

Teverelix

On August 29, 2025, we completed the acquisition of 98.6% of the issued and outstanding shares of Antev, a clinical stage biotech company developing Teverelix as a first-in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate.

Teverelix is a long-acting GnRH antagonist. Unlike GnRH agonists, which can cause a surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions.

Acute Urinary Retention Indication

An enlarged prostate can reduce the flow of urine and in some cases prevent urination, causing AUR. Teverelix operates by shrinking the prostate to allow urine flow. Currently there are no FDA-approved pharmacologic treatments to prevent AUR recurrence. The current standard of care for AUR involves catheterization, α-blockers and eventual surgical